-
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
Monday, April 14, 2025 - 5:14am | 753Read More...The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Ginkgo Bioworks Holdings Inc. (NYSE:DNA) rallying last week. What Happened: On...
-
Last Week's Notable Insider Buys: Cboe, IBM, Xerox And More
Saturday, November 7, 2020 - 3:07pm | 915Read More...Insider buying can be an encouraging signal for potential investors when markets face uncertainty. Activist investor Carl Icahn added to a stake last week. Financial companies and an options exchange operator saw insiders buying too. Conventional wisdom says that insiders and 10% shareholders...
-
Jefferies Raises PT On Charles River Laboratories To $44
Thursday, May 5, 2011 - 9:05am | 28Read More...Jefferies & Company has raised the price target on Charles River Laboratories (NYSE: CRL) from $40 to $44 and maintains its Hold rating.
-
J.P. Morgan Reports "Generally Soft" 1Q Results For Charles River Laboratories
Wednesday, May 4, 2011 - 9:07am | 103Read More...According to J.P. Morgan, Charles River Laboratories (NYSE: CRL) 1Q results were generally soft (net sales -2.2% y/y), but showed q/q improvement (+1.5% q/q) against diminished expectations (consensus $279M), with cost initiatives and share repurchases providing cushion on the bottom line. J.P....
-
Goldman Sachs Reports Charles River Laboratories EPS Higher Than Expected (CRL)
Wednesday, May 4, 2011 - 8:51am | 89Read More...According to Goldman Sachs, Charles River Laboratories (NYSE: CRL) reported 1Q EPS of $0.61 versus $0.55 EPS estimated by GS. In the report, Goldman Sachs said, "Results were helped by cost-savings actions along with share repurchases and management made no change to its non-GAAP EPS range of $2....
-
JP Morgan Raises PT On Charles River Laboratories To $38
Wednesday, May 4, 2011 - 6:42am | 28Read More...JP Morgan has raised the price target on Charles River Laboratories (NYSE: CRL) from $34 to $38 and maintains its Neutral rating.
-
Wells Fargo Raises CRL Valuation Range To $44-$45 from $42-$43
Thursday, February 10, 2011 - 11:00am | 33Read More...Wells Fargo is raising its valuation range on shares of Charles River Laboratories (NYSE: CRL) to $44-$45 from $42-$43. Charles River Laboratories currently trades at $37.73.
-
Jefferies Lowers PT Of Charles River Laboratories To $35 (CRL)
Thursday, February 10, 2011 - 10:06am | 191Read More...Jefferies its out with a report lowering the Price Target of Charles River Laboratories (NYSE: CRL) due to a pessimistic EPS outlook. The report states, “CRL reported 4Q10 non-GAAP EPS of $0.60 on net revenues of $281.7M. This excludes ~$1M loss on discontinued ops (2c) and represents a lower than...
-
Jefferies Raises PT On Charles River Laboratories To $40
Thursday, February 10, 2011 - 9:09am | 28Read More...Jefferies & Company has raised the price target on Charles River Laboratories (NYSE: CRL) from $36 to $40 and maintains its Hold rating.
-
CRL Revenue Exceeds Jefferies Estimate By $3.6M
Wednesday, February 9, 2011 - 10:23am | 108Read More...Charles River Laboratories (NYSE: CRL) posted revenue of $281.7M “which exceed our estimate by $3.6M,” Jefferies reports. “Segment revenues were mixed with RMS posting flat YoY growth (+5.7% sequential) while PCS was down 6% YoY (up sequentially after excluding Phase I),” Jefferies writes. “RMS...
-
J.P. Morgan Reports Disappointing Guidance for Charles River Laboratories
Tuesday, December 14, 2010 - 11:35am | 111Read More...J.P. Morgan published its report today on Charles River Laboratories (NYSE: CRL) after CRL reported disappointing 2011 guidance. In a note to clients, J.P. Morgan writes, "guidance for flat y/y top-line growth off a lowered 2010 estimate of $1.115B-$1.125B is below both JPMe ($1.17B) and consensus...
-
Charles River Laboratories to Report Guidance
Friday, December 10, 2010 - 9:57am | 134Read More...Jefferies is out with its report on Charles River Laboratories (NYSE: CRL) as CRL is set to report guidance on December, 14. In a report to clients, Jefferies notes, "We have picked up some minor indications of improvement in toxicology. Authorizations are higher now than 1 year ago...more so on...
-
Goldman Sachs Maintains CRL Rating And PT Ahead Of Guidance Call
Thursday, December 9, 2010 - 10:45am | 39Read More...Goldman Sachs said today that it is maintaining its Charles River Laboratories (NYSE: CRL) estimates, price target, and Neutral rating ahead of Tuesday's 2011 guidance call. Charles River Laboratories currently trades at $33.91.
